4. RELIVE – Project on liver tumors in children

International Registry of Pediatric Patients with Recurrent or Refractory Hepatoblastoma or Hepatocellular Carcinoma.

The International Multicenter Registry aims to collect data on the health of children with refractory or recurrent liver tumors. Patients with hepatoblastoma (HB), hepatocellular carcinoma (HCC), and unspecified hepatocellular neoplasm (HCN NOS) refractory or recurrent currently have unsatisfactory long-term outcomes with current treatments. Additionally, there is no generally accepted treatment for these patients. The goal of the RELIVE research project is to obtain an overview of past approaches and recently applied therapeutic strategies specifically in this context and to study short- and long-term outcomes in these patients treated with these regimens. RELIVE aims to identify the most promising therapeutic approaches with the ultimate goal of developing a clinical trial testing these approaches.

The RELIVE protocol was approved on September 21, 2020, by the Swiss Ethics Committee (CE). To date, RELIVE is active in 15 countries (Switzerland, Spain, France, Belgium, Netherlands, Poland, Germany, United Kingdom, Ireland, United States, Canada, Japan, Australia, New Zealand, and Hong Kong). A specific database, developed at the University Hospitals of Geneva (HUG), is used to collect data. Each active center has its own secure access and can enter the data of interest. As of May 2024, over 360 children from 15 countries and 64 hospitals have been enrolled in our international database. After an intense data verification period with each of the centers, the data analysis is ongoing.

The RELIVE project has also been presented at the SIOP (International Society of Pediatric Oncology) and SIOPEL (International Society of Pediatric Oncology for Liver Cancer) congresses every year since spring 2021.

[1] https://relive-international.net